Glecaprevir and Pibrentasvir
Glecaprevir and pibrentasvir is a combination antiviral used to treat hepatitis C virus (HCV) infection across all major genotypes in adults and children aged 3 and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Important warning: Mavyret can cause hepatitis B virus (HBV) to reactivate in patients who are infected with both hepatitis C and hepatitis B. This reactivation can cause severe or even fatal liver disease, including complete liver failure. It can happen even in people whose hepatitis B appeared to be resolved or inactive. Because of this, every patient must be tested for hepatitis B before starting Mavyret. Patients with both infections must be monitored closely throughout HCV treatment and for a period after it ends. Watch for symptoms such as sudden tiredness, loss of appetite, nausea, yellowing of the skin or eyes, dark-colored urine, or light-colored stools — and contact your doctor immediately if any of these occur.
📖 Glecaprevir and Pibrentasvir: Patient Information Guide
A plain-language walkthrough of Glecaprevir and Pibrentasvir — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Mavyret (glecaprevir/pibrentasvir) is a pan-genotypic hepatitis C treatment — meaning it works against all six major HCV genotypes.
- Treats acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 in adults and children 3 years and older with no cirrhosis or with compensated cirrhosis (Child-Pugh A)
- Treats genotype 1 HCV in adults and children 3 years and older who were previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor — but not both
- Can be used in patients also infected with HIV-1
- Can be used in patients with any degree of kidney disease, including those on dialysis
- Recommended for liver and kidney transplant recipients (Mavyret, with duration as directed by a specialist)
⚙️How it works▾
Mavyret combines two antiviral medicines that attack the hepatitis C virus at two different points in its life cycle. Glecaprevir is an NS3/4A protease inhibitor — it blocks an enzyme the virus needs to process its own proteins. Pibrentasvir is an NS5A inhibitor — it disables a viral protein needed for replication and assembly. Blocking both simultaneously makes it very difficult for HCV to survive, replicate, or develop resistance.
💊How it's taken▾
Mavyret is taken once daily by mouth with food — food is essential because it greatly increases absorption of both medicines. Adults and teens (12 years and older, or weighing at least 45 kg) take tablets. Younger children (ages 3 to under 12) take oral pellets in packets, with dosing based on body weight. Pellets are mixed into a small amount of thick soft food and swallowed whole — not chewed — within 15 minutes of preparation.
- Treatment-naïve patients (never treated before) typically take Mavyret for 8 weeks
- Patients who have had prior HCV treatment may need 8 to 16 weeks depending on genotype and treatment history
- Transplant recipients take Mavyret for a minimum of 12 weeks
Always follow your prescriber's exact instructions for duration and do not stop early without consulting them.
🤒Side effects — in detail▾
Most people tolerate Mavyret well — the majority of reported side effects are mild to moderate.
- Headache — the most commonly reported side effect
- Fatigue (tiredness)
- Nausea
- Diarrhea
- Itching (pruritus) — especially in patients with cirrhosis or kidney disease
- Weakness (asthenia)
- Vomiting and stomach pain — reported more often in children under 12 than in adults
Seek medical attention right away if you develop yellowing of the skin or eyes, severe abdominal swelling, confusion, or signs of a hepatitis B flare (sudden fatigue, dark urine, nausea) — these are signs of potentially serious liver problems.
⚠️Warnings & precautions▾
- Hepatitis B reactivation: If you carry the hepatitis B virus (even if it appeared resolved), treating hepatitis C with Mavyret can trigger a dangerous HBV flare. This has caused liver failure and death. All patients must be tested for HBV before starting. Those with evidence of HBV infection must be monitored closely during and after treatment.
- Liver decompensation or failure: Serious and sometimes fatal liver deterioration has been reported, mainly in patients who had advanced liver disease before starting treatment. Mavyret is contraindicated in moderate-to-severe liver impairment (Child-Pugh B or C) or a history of prior liver decompensation. Even patients with compensated cirrhosis should be monitored for symptoms like jaundice, fluid buildup in the abdomen, confusion, or bleeding.
- Reduced effectiveness with certain drugs: Carbamazepine, efavirenz, and St. John's wort can lower Mavyret levels enough to make treatment fail — these combinations are not recommended.
- Blood sugar changes in diabetics: Clearing HCV can change how your liver handles blood sugar. Diabetic patients may experience low blood sugar (hypoglycemia) and may need medication adjustments after starting Mavyret.
🔀What it interacts with▾
Mavyret has several important drug interactions — always give your doctor and pharmacist a full list of everything you take.
- Rifampin (antibiotic) — contraindicated; dramatically lowers Mavyret levels and can cause treatment failure
- Atazanavir (HIV drug) — contraindicated; raises Mavyret levels and increases risk of liver enzyme elevations
- Carbamazepine, efavirenz, phenytoin, St. John's wort — not recommended; significantly reduce Mavyret levels, risking treatment failure
- Darunavir, lopinavir, ritonavir (HIV drugs) — not recommended; raise Mavyret drug levels significantly
- Atorvastatin, lovastatin, simvastatin (cholesterol drugs) — not recommended; Mavyret raises statin levels and increases risk of muscle damage (myopathy or rhabdomyolysis)
- Rosuvastatin — can be used at a maximum dose of 10 mg daily; higher doses not recommended
- Pravastatin — reduce dose by 50% when taken with Mavyret
- Digoxin (heart drug) — needs dose reduction and close monitoring when taken with Mavyret
- Dabigatran (blood thinner) — requires careful management, particularly in kidney disease
- Contraceptives with more than 20 mcg ethinyl estradiol — not recommended; lower-dose or progestin-only contraceptives are acceptable
- Cyclosporine (immune suppressant) — Mavyret is not recommended if cyclosporine dose exceeds 100 mg/day
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- You must be tested for hepatitis B (HBsAg and anti-HBc) before starting Mavyret — a positive result requires monitoring and possibly HBV treatment
- Do not take Mavyret if you have moderate or severe liver impairment (Child-Pugh B or C) or any prior history of liver decompensation — it is contraindicated
- Tell your doctor if you have compensated cirrhosis (Child-Pugh A) or signs of portal hypertension — closer liver monitoring is needed
- Pregnancy: No adequate human data exist. Discuss risks and benefits with your doctor before starting treatment
- Breastfeeding: It is unknown whether Mavyret passes into human breast milk; weigh the benefits against potential risks with your doctor
- Children under 3 years old: Safety and effectiveness have not been established
- Kidney disease or dialysis: No dose adjustment is needed; Mavyret can be used across all levels of kidney impairment
- Older adults (65+): No dose adjustment is needed; clinical trials showed similar safety and effectiveness compared to younger adults
- People who inject drugs or are on medication-assisted treatment (MAT) for opioid use disorder: No dose adjustment is needed; buprenorphine/naloxone and methadone can be used with Mavyret without adjustment
🚑If you take too much▾
If more than the prescribed amount of Mavyret is taken, the patient should be monitored for any signs or symptoms of side effects and treated as needed. Hemodialysis does not significantly remove glecaprevir or pibrentasvir from the body. Contact your local poison control center or emergency services if an overdose is suspected.
📡Pharmacodynamics — effects in the body▾
At doses well above the normal therapeutic level, Mavyret does not meaningfully affect the heart's electrical rhythm (specifically, it does not prolong the QTc interval — the time it takes for the heart to reset between beats). This was confirmed in a dedicated cardiac study at up to twice the recommended doses, which is reassuring for patients concerned about heart-related drug effects.
🔬Pharmacokinetics — how your body processes it▾
Both glecaprevir and pibrentasvir are absorbed through the gut and reach peak blood levels about 5 hours after taking tablets (glecaprevir peaks a bit sooner — around 3 hours — with pellets). Food substantially increases absorption, which is why Mavyret must always be taken with a meal. Both drugs are cleared primarily through the liver into bile and feces, with very little leaving the body in urine. Glecaprevir has a half-life (time to clear half the drug from the body) of about 6 hours; pibrentasvir's half-life is about 13 hours. Neither drug is significantly removed by dialysis.
📦How to store it▾
Store at or below 30°C (86°F).
📄 Written from Glecaprevir and Pibrentasvir’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Glecaprevir and Pibrentasvir
144 supplements and herbal products have documented interactions with Glecaprevir and Pibrentasvir in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 103
- Minor · 38
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Glecaprevir and Pibrentasvir — the kind of thing our pharmacy team would talk through with you at the counter.
How long do I have to take Mavyret, and will it actually cure my hepatitis C? ▾
Do I really need to take it with food every single day? ▾
I've heard hepatitis B can be a problem with this medication. What do I need to know? ▾
Are there medications I absolutely cannot take while on Mavyret? ▾
What side effects should I expect, and which ones mean I should call my doctor? ▾
My child is 5 years old and has hepatitis C. Can they take Mavyret? ▾
Is Glecaprevir and Pibrentasvir available over the counter? ▾
When was Glecaprevir and Pibrentasvir first available? ▾
Who makes Glecaprevir and Pibrentasvir? ▾
💬 Answers drafted from Glecaprevir and Pibrentasvir’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Glecaprevir and Pibrentasvir comes
Glecaprevir and Pibrentasvir is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Mavyret tablets treat acute or chronic HCV genotypes 1–6 in adults and in pediatric patients 12 years and older or weighing at least 45 kg, with or without compensated cirrhosis
- Mavyret tablets are also used for genotype 1 HCV in patients previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor (but not both)
- Mavyret tablets are taken once daily by mouth, at the same time each day, with food
- Mavyret tablets are the recommended form for adults and for pediatric patients 12 years of age and older or weighing at least 45 kg
- Do not skip doses; treatment length is determined by your doctor based on your genotype, prior treatment history, and liver status
Other oral form
How this form is used
- Mavyret oral pellets treat acute or chronic HCV genotypes 1–6 in pediatric patients aged 3 to under 12 years weighing less than 45 kg
- Mavyret oral pellets may also be used by pediatric patients weighing 45 kg or more who are unable to swallow tablets
- Mavyret oral pellets are sprinkled onto a small amount of soft, thick food (such as peanut butter, cream cheese, or Greek yogurt) — the food must stick to a spoon, not drip
- Swallow the entire food-and-pellet mixture within 15 minutes of preparing it; do not chew or crush the pellets
- Mavyret oral pellets must be taken once daily with food; liquids or runny foods that the pellets could dissolve in are not recommended
- The number of pellet packets taken each day is based on the child's body weight — follow your prescriber's dosing instructions exactly
📊 Glecaprevir and Pibrentasvir across the U.S. market
How Glecaprevir and Pibrentasvir appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Glecaprevir and Pibrentasvir is used
A general measure of how commonly Glecaprevir and Pibrentasvir is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Glecaprevir and Pibrentasvir is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Glecaprevir and Pibrentasvir prescribed? Of the 1,594 medications we measure, Glecaprevir and Pibrentasvir ranks #653 by Medicaid prescriptions — more than 59% of them.
Utilization by Glecaprevir and Pibrentasvir product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
glecaprevir 100 MG / pibrentasvir 40 MG Oral Tablet Most dispensed
Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1940703
glecaprevir 50 MG / pibrentasvir 20 MG Oral Pellet
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2557906
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Glecaprevir and Pibrentasvir, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 8 listed Glecaprevir and Pibrentasvir NDCs with Medicaid activity.
🔍 Compare Glecaprevir and Pibrentasvir products
A representative set of FDA-listed product records for Glecaprevir and Pibrentasvir — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Other oral form | ||||
| PIBRENTASVIR 20 mg/1; GLECAPREVIR 50 mg | Oral | AbbVie Inc. | NDA | View NDC → |
| PIBRENTASVIR 50 mg/1; GLECAPREVIR 20 mg | Oral | AbbVie Inc. | NDA | View NDC → |
| 50; 20 mg/1; mg | Oral | AbbVie Inc. × 2 listings | NDA | View NDC → |
| 💊Tablet | ||||
| PIBRENTASVIR 40 mg/1; GLECAPREVIR 100 mg | Oral | AbbVie Inc. | NDA | View NDC → |
| PIBRENTASVIR 100 mg/1; GLECAPREVIR 40 mg | Oral | AbbVie Inc. | NDA | View NDC → |
| 100; 40 mg/1; mg | Oral | AbbVie Inc. × 2 listings | NDA | View NDC → |
| GLECAPREVIR 100 mg/1; PIBRENTASVIR 40 mg | — | Fournier Laboratories Ireland LTD | DRUG FOR FURTHER PROCESSING | View NDC → |
Showing 9 of 9 products — FDA National Drug Code Directory. See every product, package size and price: browse all 9 Glecaprevir and Pibrentasvir NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Glecaprevir and Pibrentasvir — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Glecaprevir and Pibrentasvir in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Glecaprevir and Pibrentasvir went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one exact multiple-ingredient concept (MIN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). A product with a different ingredient combination belongs on a different page.
RxCUI 1940702 2 dose forms · 2 strengths
-
Dose form (SCDF) Oral Pellet RxCUI 2557905In current FDA listingsClinical drug / strength (SCD) glecaprevir 50 MG / pibrentasvir 20 MGRxCUI 2557906 -
Dose form (SCDF) Oral Tablet RxCUI 1940701In current FDA listingsClinical drug / strength (SCD) glecaprevir 100 MG / pibrentasvir 40 MGRxCUI 1940703
Look up RxCUI 1940702 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Glecaprevir and Pibrentasvir is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Glecaprevir and Pibrentasvir belongs to the Hepatitis C Virus NS3/4A Protease Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. AbbVie Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.